AI radiology company Aidoc revealed on Tuesday that the US Food and Drug Administration (FDA) has cleared the world's first AI solution for the treatment of cervical spine (C-spine) fractures.
This latest US FDA 510(k) clearance is reportedly the company's third in nine months and follows the recent US FDA clearance of the pulmonary embolism solution.
The company added that the AI-powered triage automatically prioritizes critical cases, ensuring that they are diagnosed by a radiologist in the most timely manner.
According to the company, the recent studies show that 54% of radiologists feel "burnt out" due to long work hours and on-the-job stress. AI-driven workflow triage is especially beneficial for empowering the radiologist by maintaining quality across the workflow, increasing confidence in treating critical patients on time, while making radiologists' work a lot more rewarding and less tedious.
In conjunction, the company's CEO Elad Walach will present its suite of AI-based workflow solutions at booth 513on an Ask Industry panel on the topic of 'AI in Practice – Where Are We Now?' at the SIIM 2019 annual meeting.
Egetis Therapeutics receives FDA approval for EMCITATE in MCT8 deficiency
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
FDA approves WELIREG and LENVIMA combination for previously treated advanced renal cell carcinoma
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis